Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 1,400 | $437,318 | 0.01% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $105.67 | 5,523 | $583,629.22 | 161,234 | 2025-05-09 | Filing | |
| $104.53 | 2,307 | $241,149.56 | 155,711 | 2025-05-09 | Filing | |
| $104.57 | 1,680 | $175,677.60 | 153,404 | 2025-05-09 | Filing | |
| $104.40 | 500 | $52,200.00 | 27,932 | 2025-05-09 | Filing | |
| $103.89 | 1,000 | $103,890.00 | 27,432 | 2025-05-09 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $320.43 | 700 | $224,298.27 | 108,758 | 2026-11-02 | Filing | |
| $320.49 | 50 | $16,024.50 | 109,458 | 2026-10-30 | Filing | |
| $320.42 | 1,209 | $387,384.39 | 109,508 | 2026-10-30 | Filing | |
| $320.24 | 52 | $16,652.48 | 110,717 | 2026-10-30 | Filing | |
| $318.23 | 50 | $15,911.50 | 110,769 | 2026-10-30 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 658,556 | $205,713,138 | 1.33% | |
| 2. | 551,225 | $172,186,097 | 3.99% | |
| 3. | 50,367,000 | $84,804,647 | 0.57% | |
| 4. | 126,842 | $39,621,636 | 0.02% | |
| 5. | 69,350 | $21,662,860 | 2.68% |